Tat'Yana Nikolaevna Krasnova

Tat'Yana Nikolaevna Krasnova

Auto-generated profile, based on publicly available information

Tat'Yana Nikolaevna Krasnova

Lomonosov Moscow State University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NCNatalia V. Chebotareva
Natalia V. Chebotareva
AVAnatoliy Vinogradov
Anatoliy Vinogradov
LTLarisa Tsoy
Larisa Tsoy
VVVladimir Varshavskiy
Vladimir Varshavskiy
ESEkaterina Stolyarevich
Ekaterina Stolyarevich
Alexey S. KononikhinAlexey S. Kononikhin
Alexey S. Kononikhin
It is suggested that activated CD44+ cells play a profibrogenic role in the pathogenesis of active glomerulopathies. Complement activation is also involved in renal fibrogenesis. The aim of the study was to evaluate the role of the activation of CD44+ cells in the kidney tissue and complement components’ filtration to the urine as factors of renal tissue fibrosis in patients with glomerulopathies. In total, 60 patients with active glomerulopathies were included in our study: 29 patients with focal segmental glomerulosclerosis (FSGS), 10 patients with minimal change disease (MCD), 10 patients with membranous nephropathy (MN), and 11 patients with IgA nephropathy. The immunohistochemical peroxidase method was used to study the expression of CD44+ in kidney biopsies. Components of complement were analyzed in urine by the multiple reaction monitoring (MRM) approach using liquid chromatography. Strong CD44 expression was noted predominantly in PEC and mesangial cells (MC) in patients with FSGS, and to a lesser extent, in patients with MN and IgA nephropathy, and it was absent in patients with MCD. Expression of profibrogenic CD44+ in glomeruli correlated with the levels of proteinuria and complement C2, C3, and C9 components, and CFB and CFI in urine. The CD44+ expression scores in the renal interstitium correlated with the level of C3 and C9 components of complement in the urine and the area of tubulo-interstitial fibrosis. The strongest expression of CD44+ was found in the glomeruli (MC, PEC, and podocytes) of patients with FSGS compared with other glomerulopathies. The CD44 expression score in the glomeruli and interstitium is associated with high levels of complement components in the urine and renal fibrosis.

6 September 2022 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
TBTatiana Beketova
Tatiana Beketova
NLN. O. Levina
N. O. Levina
DLD. O. Ladygina
D. O. Ladygina
VBV. V. Babak
V. V. Babak
MBM. F. Beketova
M. F. Beketova
TKT. N. Krasnova
T. N. Krasnova
Coronavirus disease 2019 (COVID-19) can manifest with a wide range of extrapulmonary symptoms and have longterm consequences (so-called post-covid syndrome (PCS) or “long COVID-19”). Manifestations of PCS show a wide clinical spectrum and include cardiac, pulmonary, neurological, gastrointestinal, dermatological, mental symptoms, vascular thrombosis and avascular necrosis (AVN) of the bones.We present our own observations of the development of bone’s AVN in 3 patients who underwent COVID-19 with bilateral lung disease, in whom after 4–6 months the first signs of AVN were noted and characterized by a progressive multifocal lesion, which was accompanied by an increase of C-reactive protein concentration.The pathogenetic mechanisms of AVN development in the framework of PCS are discussed. The importance of conservative and surgical methods in the treatment of the disease are considered. Since the development of AVN of various localizations with a long latent period is possible after COVID-19, long-term monitoring of patients is required. Further study of the problem of PCS in general and AVN in particular is required.

17 August 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
KNKirill S. Nezhdanov
Kirill S. Nezhdanov
LMLudmila Y. Milovanova
Ludmila Y. Milovanova
LSLeonid A. Strizhakov
Leonid A. Strizhakov
TKTatiana N. Krasnova
Tatiana N. Krasnova
The article describes major milestones in acknowledgment of pathophysiological relationship between heart and kidneys since Ancient Egypt till our time and history of term cardiorenal syndrome (CRS). First references about kidney and heart functions could be dated to 13 BC when Hippocrates mentioned them. In the XIV century Gentile da Foligno proposed a hypothesis about functional interconnection between heart and kidneys. In the XVIII century Richard Bright described the link between myocardial hypertrophy and kidneys diseases. Frederic Justin Collet was the first one who used the term cardiorenal in his article in 1903. In Russia, I.I. Stolnikov conducted his experiments about myocardial hypertrophy and kidneys ischemia in 1880. Famous Russian internist, E.M. Tareev, devoted several paragraphs to cardiorenal interactions in his fundamental manuals Anemia in Brights disease (1929) and Hypertension (1948). The research on this topic was continued by Tareevs followers: N.A. Mukhin, V.S. Moiseev, more recent successors Zh.D. Kobalava, S.V. Moiseev, V.V. Fomin, S.V. Villevalde and others. Their contribution resulted in development of first Russian clinical guidelines on cardio and nephroprotection in CRS in 2014. In 2008 consensus of Acute Disease Quality Initiative summarized current experience on CRS. Today, research on controversial classification questions, biomarkers and other aspects of CRS continues.

3 December 2015 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
LSLarisa Mikhaylovna Samokhodskaia
Larisa Mikhaylovna Samokhodskaia
ESEkaterina Evgen'Evna Starostina
Ekaterina Evgen'Evna Starostina
Elena YarovayaElena Yarovaya
Elena Yarovaya
TKTat'Yana Nikolaevna Krasnova
Tat'Yana Nikolaevna Krasnova
NMNikolay Alekseevich Mukhin
Nikolay Alekseevich Mukhin
VSViktor Antonovich Sadovnichy
Viktor Antonovich Sadovnichy
Обоснование. В настоящее время большое внимание уделяется поиску генетических факторов, объясняющих течение хронического гепатита С (ХГС). Цель исследования: оценить прогностическую значимость носительства комбинаций аллельных вариантов генов IL 1b, IL 6, IL 10, TNF α, HFE, TGF b, ATR1, NOS3, CYBA, AGT, MTHFR, FII, FV, FVII, FXIII, ITGA2, ITGB3, FBG, PAI на прогрессирование фиброза печени при ХГС. Материалы и методы: 118 пациентов с ХГС разделены на группы с быстрым и медленным (скорость фиброза ≥0,13 и <0,13 ед. фиброза/год; n =64 и n =54, соответственно) фиброзом. Выполнено определение полиморфизма. Статистическую обработку результатов проводили с использованием пакетов программ Statistica 10. Результаты. У больных с быстрым фиброзом в сравнении с группой с медленным чаще встречались аллель А (р =0,012) и мутантный генотип АА (р =0,024) гена AGT G-6T, также в данной группе чаще выявляли аллель Т (р =0,013) и генотип МТ+ТТ гена AGT 235 M/T (р =0,005). Больные с генотипом ТТ гена CYBA 242 C/T имели более высокую скорость фиброза по сравнению с больными с генотипом СС+СТ (р =0,02). В ходе анализа выявлено протективное влияние гомозиготы ТТ гена ITGA2 807 C/T на темпы фиброза (р =0,03). Наблюдались тенденции к различию по встречаемости аллелей и генотипов полиморфных маркеров TGFb +915 G/С, FXIII 103 G/T, PAI -675 5G/4G между двумя группами. Для остальных генов достоверных отличий не обнаружено. В дальнейшем построена математическая модель, учитывающая протективное и профиброгенное влияние генов, в также влияние генотипа вируса. Выявлена корреляция между суммой баллов в этой модели и темпом прогрессирования фиброза в печени (R =0,39, p =0,000). Заключение: предложенная математическая модель может прогнозировать течение болезни.

28 April 2023 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
TBTatiana Beketova
Tatiana Beketova
NLN. О. Levina
N. О. Levina
MDM. V. Dubinskaia
M. V. Dubinskaia
YUYu. A. Uskova
Yu. A. Uskova
IRI. V. Rozanova
I. V. Rozanova
TKT. N. Krasnova
T. N. Krasnova
The problem of prevention of coronavirus disease 2019 (COVID-19) in patients with immune-mediated inflammatory rheumatic diseases (IMRD) remains highly relevant. The presence of IRD is associated with a high risk of disease and severe course of COVID-19 during immunosuppressive treatment, primarily anti-B cell therapy with rituximab (RTX), and a low level of post-vaccination response in such patients. A new strategy for the prevention and treatment of COVID-19 are virus-neutralizing monoclonal antibodies to coronavirus; currently, combined long-acting monoclonal antibodies tixagevimab and cilgavimab (Evusheld) are registered for prevention in the world and the Russian Federation. . Tixagevimab and cilgavimab (TC) show neutralizing activity against SARS-CoV-2, including the Omicron strain, primarily its variants BA.4, BA.5, BA.2.75 ("Centaur").Objective – to evaluate the efficacy and safety of TC for pre-exposure prophylaxis of COVID-19 in rheumatic patients receiving RTX, based on a prospective observational study.Materials and methods. The main group included 86 patients with various IMRD receiving RTX: 50 of them had ANCA-associated systemic vasculitis (AAV), 15 – rheumatoid arthritis, 9 – Sjogren’s syndrome (SS), 4 – IgG4-related disease, 3 – systemic lupus erythematosus (SLE), 3 – dermatomyositis (DM), 2 – systemic scleroderma (SSD). Median age was 59 (19–82) years; male : female ratio – 1:1,8. From March 26 to August 30 2022, patients received a single intramuscular injection of TC in a total dose of 300 mg, mainly after RTX (in 52% of cases, in 28% on the next day after RTX). The control group included 42 patients with AAV (median age – 45 (35–71) years; male : female ratio – 1:1), also treated with RTX, who did not receive pre-exposure prophylaxis of TC. The duration of observation was 7 months, until November 1 2022. At this time, 98% of confirmed cases of coronavirus in the Russian Federation were Omicron. A telephone and/or online survey of patient has been conducted to detect cases of COVID-19 and adverse reactions.Results. In the TC group, confirmed coronavirus infection have been detected in 17 (20%) patients (AAV – 10, SS – 3, SSD – 2, SLE – 1, DM – 1), with fever in 7 (8%), only in one case hospitalization was required (lung damage was not detected in computed tomography), in two cases, according to CT mild lung damage (CT 1–2), there were no deaths. Good TC’s tolerability was noted, signs not associated with COVID-19 or progression of IMRD after administration of TC were observed in 8 (9%) patients (GPA – 3 MPA – 1, RA – 2, SLE – 1, IgG4-related disease – 1), adverse reactions definitely associated with the use of TC were not found. The most serious event not associated with coronavirus infection was the progression of polyneuropathy in a patient with RA. In the control group, 3 (7%) patients were diagnosed with COVID-19, one with severe lung injury (CT 3, pulmonary embolism) and death.Conclusions. The data of clinical studies and our own clinical experience evidence the effectiveness of the use of a combination of long-acting monoclonal antibodies TC (Evusheld), registered for indications for pre-exposure prophylaxis and treatment of COVID-19. Patients with IMRD treated with RTX have a favorable safety profile of TC. The introduction of virus-neutralizing monoclonal antibodies, a new drug class for the prevention and treatment of infectious diseases, opens significant prospects for improving the prognosis of patients with IRD.

10 October 2024 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OGOlga A. Georginova
Olga A. Georginova
ASAleksandra D. Savina
Aleksandra D. Savina
TKTatyana N. Krasnova
Tatyana N. Krasnova
LGLyalya A. Gabbasova
Lyalya A. Gabbasova
AAArtashes G. Armaganov
Artashes G. Armaganov
Background: The importance of timely diagnosis of rheumatic diseases is beyond any doubt. However, in the real practice the time from manifestation of the first symptoms to the assessment by a rheumatologist and treatment administration often exceeds the window of opportunity for disease control. At the moment, there has been no Russian-language questionnaire that would allow a primary care physician to suspect a rheumatic disease manifesting with an articular syndrome. Aim: To develop, validate and test a questionnaire to identify risk factors for joint disorders and related conditions. Methods: From November 2022 to April 2024, we performed the study on the image-based questionnaire on identification of the risk factors for joint syndromes and associated conditions (ARTROVIS), which we have developed for early detection of both joint syndromes, as well as comorbid conditions associated with elevated serum uric acid levels (hyperuricemia). The initial test version of the questionnaire was tested in a focus group of respondents (n = 20) who came for regular medical examination. Based on the results of this face validity assessment, we corrected the wording of 10 questionnaire items. At the second study step, we assessed the primary validity and reliability of the questionnaire in a group of 41 rheumatology patients. The third study step involved 828 respondents (408 men and 420 women, median age 19 [18,0; 20,0] years; 21% with joint syndromes), who came for routine medical examination. The reliability of the questionnaire, its face and discriminant validity, as well as sensitivity and specificity (the ROC analysis) were assessed from 827 questionnaires included in the final processing (one was excluded due to questionnaire completion defects). Results: The self-report questionnaire for patients (ARTROVIS) has 24 items aimed at collecting social and demographic data, identifying risk factors for non-communicable diseases, assessing genetic aspects, identifying complaints from various organ systems, providing information on medical treatments taken by the patient (non-steroid anti-inflammatory agents, diuretics, antihypertensives, glucocorticosteroids, chemotherapy and radiation therapy), as well as an additional question for women on current pregnancy pathology. The questionnaire contains visual aids (colored photos) that facilitate the detection of clinical signs of autoimmune (psoriatic arthritis, Reynolds’s syndrome) and inflammatory rheumatic disease (gout), as well as the differential diagnosis of the joint syndrome. The assessment of face validity of the questionnaire showed the total number of missed answers of 3.42%; 62.85% of the respondents gave their full answers to all items. Good discriminant validity was demonstrated. The ROC analysis showed high correlation between the questionnaire score and the presence of a joint syndrome: the area under the curve was 0.884. The Cronbach’s alfa was 0.798, which is sufficient for a medical questionnaire. Conclusion: We have performed the approbation and standardization of the questionnaire to identify risk factors for the joint syndrome and related comorbidities by assessing its validity and reliability. The ARTROVIS as a self-report questionnaire can be used in primary care as a tool enabling general practitioners and internists to decide on further patient routing to corresponding specialists.